title: Paclitaxel in anthracycline-treated breast cancer patients.
abstract: Between May 1995 and July 1997, paclitaxel (TX) (175 mg/m2 by 3 h i. v. infusion every 21 days) was administered to 70 consecutive patients (median age: 57 years) previously treated with the FEC regimen (cyclophosphamide and 5-fluorouracil, 600 mg/m2, plus epirubicin, 60 or 120 mg/m2) as an adjuvant setting or as a first-line therapy for metastatic disease. Sixty-eight patients were evaluable for response, while two died early. Patients received a median of 4.7 (3-12 course) of TX for a total of 211 courses. The overall response and stable disease rate was 54% in 11 patients, who relapsed following adjuvant FEC, and 60% in 57 patients, who received FEC as first treatment for their metastatic disease. No complete respose was obtained. In patients pretreated for metastatic disease, response and stable disease rates were similar irrespective of previous response to FEC. Main hematologic toxicity of TX was of short duration, grade II/III leukopenia (86% of patients) and non-hematologic toxicity was grade II/III peripheral neuropathy, related to the cumulative dose of TX. At this schedule, TX offers a significant rate of partial responses or disease stabilization in patients with metastatic breast cancer previously treated with FEC.
authors.affiliation: Medicina Interna e Oncologia Medica, Policlinico S. Matteo, 27100 Pavia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pugliese
authors.forename: S
authors.initials: S
authors.lastname: Brugnatelli
authors.forename: M
authors.initials: M
authors.lastname: Giordano
authors.forename: M
authors.initials: M
authors.lastname: Danova
authors.forename: A
authors.initials: A
authors.lastname: De Monte
authors.forename: A
authors.initials: A
authors.lastname: Richetti
authors.forename: S
authors.initials: S
authors.lastname: Fava
authors.forename: E
authors.initials: E
authors.lastname: Rinaldi
authors.forename: V
authors.initials: V
authors.lastname: Fregoni
authors.forename: C
authors.initials: C
authors.lastname: Epifani
authors.forename: A
authors.initials: A
authors.lastname: Riccardi
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel